Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $38.00 at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI) had its price objective lifted by HC Wainwright from $36.00 to $38.00 in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $14.88 on Friday. The stock has a market capitalization of $191.65 million, a price-to-earnings ratio of -20.67 and a beta of 1.64. The stock’s 50-day simple moving average is $15.40 and its two-hundred day simple moving average is $14.70. Greenwich LifeSciences has a 52-week low of $7.58 and a 52-week high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). As a group, equities analysts forecast that Greenwich LifeSciences will post -0.75 earnings per share for the current fiscal year.

Insider Transactions at Greenwich LifeSciences

In related news, CEO Snehal Patel acquired 5,500 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were purchased at an average price of $13.18 per share, with a total value of $72,490.00. Following the completion of the purchase, the chief executive officer now directly owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased 183,825 shares of company stock valued at $2,627,473 over the last quarter. 52.86% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. raised its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after buying an additional 1,420 shares during the period. Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at approximately $264,000. Finally, Rhumbline Advisers bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at approximately $117,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.